Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

石四藥集團有限公司
SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT
UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the "Board") of SSY Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group has obtained the approval for drug production and registration for Norepinephrine Bitartrate Injection (1ml:2mg) from the National Medical Products Administration of China (the "NMPA"), being under type 3 chemical drug and regarded as passing the consistency evaluation. It is mainly used for blood pressure control in certain acute hypotensive states.

There is a strong clinical demand for adrenaline-based emergency drugs with an estimated annual usage of approximately 200 million pieces in China. The Group's Norepinephrine Bitartrate Injection (4ml:8mg) has been approved earlier, and this new 1ml:2mg of smaller specification is better suited for precise dosing scenarios such as initial administration, dose reduction titration and pediatric patients, improving clinical medication flexibility of our products. As of now, the Group has a complete adrenaline series with four types of products: adrenaline hydrochloride injection, norepinephrine bitartrate injection, isoproterenol hydrochloride injection and phenylephrine hydrochloride injection, resulting a significant advantage in product portfolio of this series. The Group also possess its own bulk pharmaceuticals support for these four types in this series. Being one of the few manufacturers in China with integrated production capabilities of bulk pharmaceuticals and preparations for these four types in this series, the Group has a significant advantage in terms of a self-controllable supply chain.

In addition, the Board is also pleased to announce that the NMPA has approved the addition of indication for the Group's Paracetamol and Mannitol Injection (two specifications of 50ml and 100ml), which is relieving moderate to severe postoperative pain in adults in combination with opioid analgesics.

Before this approval, the Group's Paracetamol and Mannitol Injection was approved for its indication in relieving fever in adults. Being the first PRC entity with approval for both antipyretic and analgesic indications, the Group's Paracetamol and Mannitol Injection will have a broadened scope of applications and an expanded market size with this approval.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 17 November 2026

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Meng Guo, Mr. Chow Hing Yeung, Ms. Qu Wanrong and Mr. Wu Hengyao as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.